| pubmed-article:8871619 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C1332717 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C1706438 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C0085358 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C0018133 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C1332714 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C1413243 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C1366561 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C1413244 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C2698600 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C0439851 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C1552596 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C1947931 | lld:lifeskim |
| pubmed-article:8871619 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:8871619 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:8871619 | pubmed:dateCreated | 1996-12-17 | lld:pubmed |
| pubmed-article:8871619 | pubmed:abstractText | Efficient T cell proliferation requires costimulation via CD28/B7 or other pathways. Graft-vs-host disease (GVHD) is caused by activated donor T cells. We have found that the infusion of anti-B7.1 (CD80) + anti-B7.2 (CD86) mAb is effective in eliminating GVHD lethality induced by either CD8+ or CD4+ T cells. Donor CD4+ and CD8+ T cell expansion was inhibited by almost 100-fold as measured by enumerating thoracic duct lymphocytes (TDL) obtained early post-transplant. TDL retained anti-host responsiveness indicating that not all T cells were anergic. Although anti-CD80 or anti-CD86 mAb individually were ineffective in preventing CD8+ T cell GVHD lethality, each mAb was partially effective in CD4+ T cell-mediated GVHD. Because CD80 expression was found to be up-regulated on donor CD4+ TDL post-transplant, the GVHD capacity of donor CD4+ T cells deficient in CD80 was tested and found to be reduced similarly to that seen with anti-CD80 mAb. These studies demonstrate that anti-CD80 + anti-CD86 mAb infusion is effective in preventing GVHD lethality by inhibiting donor CD4+ or CD8+ T cell expansion and provide the first evidence that CD80 expression on donor T cells is critical for optimal GVHD lethality. | lld:pubmed |
| pubmed-article:8871619 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8871619 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8871619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8871619 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8871619 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:8871619 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:8871619 | pubmed:author | pubmed-author:GanzP OPO | lld:pubmed |
| pubmed-article:8871619 | pubmed:author | pubmed-author:ValleraD ADA | lld:pubmed |
| pubmed-article:8871619 | pubmed:author | pubmed-author:KorngoldRR | lld:pubmed |
| pubmed-article:8871619 | pubmed:author | pubmed-author:TaylorP APA | lld:pubmed |
| pubmed-article:8871619 | pubmed:author | pubmed-author:SharpeA HAH | lld:pubmed |
| pubmed-article:8871619 | pubmed:author | pubmed-author:BlazarB RBR | lld:pubmed |
| pubmed-article:8871619 | pubmed:author | pubmed-author:Panoskaltsis-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8871619 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8871619 | pubmed:volume | 157 | lld:pubmed |
| pubmed-article:8871619 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8871619 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8871619 | pubmed:pagination | 3250-9 | lld:pubmed |
| pubmed-article:8871619 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:meshHeading | pubmed-meshheading:8871619-... | lld:pubmed |
| pubmed-article:8871619 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8871619 | pubmed:articleTitle | Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells. | lld:pubmed |
| pubmed-article:8871619 | pubmed:affiliation | Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA. | lld:pubmed |
| pubmed-article:8871619 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8871619 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8871619 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8871619 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8871619 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8871619 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8871619 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8871619 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8871619 | lld:pubmed |
